跳到正文
原文
Endpoints News 生物医药· Elizabeth Cairns·· 23 天前AI 评分50

礼来 triple-G 药物 retatrutide 在糖尿病对比中表现优于诺和诺德 Ozempic

Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes

AI 导读

Endpoints News 报道称,礼来的 triple-G 药物 retatrutide 在糖尿病相关对比中表现优于诺和诺德的 Ozempic,该比较基于跨试验数据。原文为付费内容,未披露具体疗效数据、试验名称与期别。

正文

Eli Lil­ly’s re­ta­tru­tide, the in­cretin shot that has al­ready proven its ef­fec­tive­ness against oth­er as­sets on a cross-tri­al ba­sis, has ce­ment­ed its util­i­ty in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news